Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple

Farshid Noorbakhsh1, Shigeki Tsutsui, Nathalie Vergnolle

  • 1Department of Medicine, University of Alberta, Edmonton, Alberta T6G 2S2, Canada.

Insights

Proteinase-activated receptor 2 (PAR2) exacerbates multiple sclerosis (MS) by increasing neuroinflammation, demyelination, and axonal injury. Inhibiting PAR2 in experimental autoimmune encephalomyelitis (EAE) models ameliorated disease severity.

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Proteinase-activated receptors (PARs) modulate inflammation and neurodegeneration.
  • The specific role of PAR2 in multiple sclerosis (MS) pathogenesis remains largely unexplored.

Purpose of the Study:

  • To investigate the role of PAR2 in the pathogenesis of MS in humans and experimental autoimmune encephalomyelitis (EAE) in mice.

Main Methods:

  • Assessed PAR2 expression in human MS and murine EAE CNS tissue.
  • Compared immune gene expression in wild-type (WT) and PAR2 knockout (KO) macrophages and astrocytes.
  • Evaluated EAE severity, neuroinflammation, demyelination, and axonal injury in PAR2 WT and KO mice.

Main Results:

  • PAR2 expression was elevated in astrocytes and macrophages in MS and EAE CNS.
  • PAR2 KO macrophages produced more interleukin-10; PAR2 activation released oligodendrocyte cytotoxins.
  • PAR2 WT mice exhibited exacerbated EAE with increased CNS inflammation, demyelination, axonal injury, and a more severe disease phenotype compared to KO littermates.

Conclusions:

  • CNS PAR2 expression promotes neuroinflammation, demyelination, and axonal injury in MS pathogenesis.
  • Targeting PAR2 may offer a therapeutic strategy for multiple sclerosis.